Pichinde Virus Reverse Genetics for Arenavirus Vaccine Development
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for arenavirus infections, such as those caused by Lassa virus and Junin virus, lack effective therapeutic options, with available antiviral drugs having significant side effects and limited availability, and there are no vaccines approved for human use due to high containment requirements and cost associated with working with pathogenic arenaviruses.
Innovation Solution
A genetically engineered Pichinde virus with three ambisense genomic segments, including coding regions for Z protein, RNA-dependent RNA polymerase, nucleoprotein, and glycoprotein, is developed, along with a reverse genetics system using vectors to produce infectious virus particles that can encode antigens, allowing for the generation of vaccines and immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pathogenic arenaviruses are used for vaccine development and treatment studies, then relevant immunological data can be obtained, but high containment requirements (BSL-4) and high costs are required
Solution Approach 1:
The patent uses Pichinde virus as an intermediary model system that mimics pathogenic arenavirus behavior without requiring BSL-4 containment. The virus serves as a safe surrogate that produces comparable immunological data to pathogenic arenaviruses while allowing work in BSL-2 laboratories, thus mediating between safety requirements and research relevance
Solution Approach 2:
The patent creates a copy of the pathogenic arenavirus system using Pichinde virus, which replicates the essential biological and immunological characteristics of pathogenic arenaviruses. This copying approach allows researchers to study arenavirus-induced hemorrhagic fevers and vaccine responses without handling actual pathogenic strains
2Reliability
If ribavirin is administered to treat arenavirus infections, then some beneficial antiviral effects are achieved, but many side effects occur and early administration is required
Solution Approach 1:
The patent employs vaccine strategies that induce protective immunity before infection occurs, eliminating the need for post-infection drug intervention. By pre-establishing immune protection through vaccination, the system prevents the need for ribavirin administration and its associated side effects and timing constraints
3Ease of operation
If reverse genetics systems are developed for Pichinde virus, then vaccine production and immune response studies become feasible in BSL-2 laboratories, but system complexity increases
Solution Approach 1:
The patent divides the Pichinde virus genome into separate cDNA segments that can be independently manipulated and reassembled. This segmentation allows the reverse genetics system to be constructed from modular components, facilitating safe manipulation in BSL-2 laboratories while maintaining the ability to produce infectious virus particles for vaccination studies
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The genetically engineered Pichinde virus system enables the production of vaccines that induce strong humoral and cell-mediated immunity with minimal anti-vector immunity, providing protection against lethal challenges from influenza and other viral pathogens, and can be used in prime-boost vaccination strategies.
Implementation Method 1
The large L protein (∼200 kDa) encoded also on the L segment is the RNA-dependent RNA polymerase (RdRp) protein that is required for viral RNA synthesis
Implementation Method 2
The nucleoprotein (NP) of the S segment encapsidates viral genomic RNAs
Implementation Method 3
The glycoprotein (GPC) encoded on the small (S) segment is post-translationally processed into a stable signal peptide (SSP), the receptor-binding G1 protein, and the transmembrane G2 protein
Implementation Method 4
The Z protein produced from the large (L) genomic segment is a small RING-domain containing matrix protein that mediates virus budding
Data Source
AI summary
Provided herein are genetically engineered Pichinde viruses that include three ambisense genomic segments. The first genomic segment includes a coding region encoding a Z protein and a coding region encoding a L RdRp protein. The second genomic segment includes a coding region encoding a nucleoprotein (NP) and the third genomic segment includes a coding region encoding a glycoprotein. Each of the second and third genomic segments optionally include an additional coding region that may encode an antigen or a detectable marker. Also provided herein is a reverse genetics system for making a genetically engineered Pichinde virus, and a collection of vectors that can be used to produce a genetically engineered Pichinde virus. Further provided are methods for using a reverse genetics system, and methods for producing an immune response in a subject.